Goodman Chair of Excellence Professor of Medicine
Director, Division of Connective Tissue Diseases
Department of Medicine

MEMPHIS TN 381630000
Tel: (901) 448-5774


  • PostDoc, Duke University Medical Center, Durham, NC (Howard Hughes Medical Institute), Med. Res./Rheum. Fellow
  • None, Tulane Division Charity Hospital, New Orleans, LA, Intern & Resident
  • M.D., Cornell University Medical College, NY, NY, Medicine
  • A.B., West Virginia University, Morgantown, WV, Pre-Medicine

My Current CV

Clinical Care Specialty/Interest

Rheumatology Attending Physician supervising and teaching Rheumatology Fellows, medical residents, and medical students in both outpatient clinics and of patients admitted to hospitals.

Research Description

Research into mechanisms of autoimmune arthritis using preclinical models of rheumatoid arthritis and therapeutic approaches of fibrosis and autoimmunity and their treatment in systemic sclerosis are actively being studied using preclinical models with translation to patients with this disease.

Research Keywords

fibrosis, cytokines, lymphocytes, macrophages, fibroblasts, immune tolerance, vitamin D analogs

Research Interest/Specialty

Basic and translational research immunology and cell biology relative to rheumatoid arthritis and systemic sclerosis (scleroderma), including disease mechanisms and therapeutic approaches.


  1. Skobowiat, C, Postlethwaite, AE, Slominski, AT. Skin Exposure to Ultraviolet B Rapidly Activates Systemic Neuroendocrine and Immunosuppressive Responses. Photochem Photobiol, 2016.
  2. Lin Z, Marepally SR, Kim TK, Janjetovic Z, Oak AS, Postlethwaite AE, Myers LK, Tuckey RC, Slominski AT, Miller DD, Li W. Design, synthesis and biological activities of novel gemini 20S-hydroxyvitamin D3 analogs. Anticancer Res, 3 (Mar 36), 877-86, 2016.
  3. 1. Schlabritz-Loutsevich NE, Comuzzie AG, Mahaney MM, Hubbard GB, Dick EJ Jr, Kocak M, Gupta S, Carrillo M, Schenone M, Postlethwaite A, Slominski A. Serum vitamin D concentrations in baboons (papio spp.) during pregnancy and obesity. Comp Med, 2 (66), 137-42, 2016.
  4. Pattanaik, D, Brown, M, Postlethwaite, BC, Postlethwaite, AE. Pathogenesis of Systemic Sclerosis. Front Immunol, 6, 272, 2015.
  5. Lin, Z, Marepally, SR, Ma, D, Myers, LK, Postlethwaite, AE, Tuckey, RC, Cheng, CY, Kim, TK, Yue, J, Slominski, AT, Miller, DD, Li, W. Chemical Synthesis and Biological Activities of 20S,24S/R-Dihydroxyvitamin D3 Epimers and Their 1α-Hydroxyl Derivatives. J Med Chem, 58 (19), 7881-7, 2015.
  6. Slominski, AT, Kim, TK, Li, W, Postlethwaite, A, Tieu, EW, Tang, EK, Tuckey, RC. Detection of novel CYP11A1-derived secosteroids in the human epidermis and serum and pig adrenal gland. Sci Rep, 5, 14875, 2015.
  7. Wang, L, Liu, H, Jiao, Y, Wang, E, Clark, SH, Postlethwaite, AE, Gu, W, Chen, H. Differences between Mice and Humans in Regulation and the Molecular Network of Collagen, Type III, Alpha-1 at the Gene Expression Level: Obstacles that Translational Research Must Overcome. Int J Mol Sci, 16 (7), 15031-56, 2015.
  8. Slominski, A, Postlethwaite, AE. Skin under the sun: when melanin pigment meets vitamin D. Endocrinology, 156 (1), 1-4, 2015.
  9. Jiao, Y, Chen, H, Gu, T, Wang, L, Postlethwaite, A, Gu, W. Molecular network of important genes for systemic sclerosis-related progressive lung fibrosis. BMC Res Notes, 8, 544, 2015.
  10. Sun, S, Jiao, Y, Wei, W, Postlethwaite, AE, Gu, W, Sun, D. Comparison of LAIR-1 genetic pathways in murine vs human internal organs. Gene, 552 (1), 140-5, 2014.
  11. Slominski, AT, Kim, TK, Li, W, Yi, AK, Postlethwaite, A, Tuckey, RC. The role of CYP11A1 in the production of vitamin D metabolites and their role in the regulation of epidermal functions. J Steroid Biochem Mol Biol, 144 Pt A, 28-39, 2014.
  12. Marion, TN, Postlethwaite, AE. Chance, genetics, and the heterogeneity of disease and pathogenesis in systemic lupus erythematosus. Semin Immunopathol, 36 (5), 495-517, 2014.
  13. Slominski, AT, Kim, TK, Takeda, Y, Janjetovic, Z, Brozyna, AA, Skobowiat, C, Wang, J, Postlethwaite, A, Li, W, Tuckey, RC, Jetten, AM. RORα and ROR γ are expressed in human skin and serve as receptors for endogenously produced noncalcemic 20-hydroxy- and 20,23-dihydroxyvitamin D. FASEB J, 28 (7), 2775-89, 2014.
  14. Chen, J, Wang, J, Kim, TK, Tieu, EW, Tang, EK, Lin, Z, Kovacic, D, Miller, DD, Postlethwaite, A, Tuckey, RC, Slominski, AT, Li, W. Novel vitamin D analogs as potential therapeutics: metabolism, toxicity profiling, and antiproliferative activity. Anticancer Res, 34 (5), 2153-63, 2014.
  15. Slominski, A, Zbytek, B, Nikolakis, G, Manna, PR, Skobowiat, C, Zmijewski, M, Li, W, Janjetovic, Z, Postlethwaite, A, Zouboulis, CC, Tuckey, RC. Steroidogenesis in the skin: implications for local immune functions. J Steroid Biochem Mol Biol, 137, 107-23, 2013.
  16. Tang, B, Kim, S, Hammond, S, Cullins, DL, Brand, DD, Rosloniec, EF, Stuart, JM, Postlethwaite, AE, Kang, AH, Myers, LK. Characterization of T cell phenotype and function in a double transgenic (collagen-specific TCR/HLA-DR1) humanized model of arthritis. Arthritis Res Ther, 16 (1), R7, 2013.
  17. Slominski, A, Janjetovic, Z, Tuckey, RC, Nguyen, MN, Bhattacharya, KG, Wang, J, Li, W, Jiao, Y, Gu, W, Brown, M, Postlethwaite, AE. 20S-hydroxyvitamin D3, noncalcemic product of CYP11A1 action on vitamin D3, exhibits potent antifibrogenic activity in vivo. J Clin Endocrinol Metab, 98 (2), E298-303, 2013.
  18. Slominski, A, Kim, TK, Zmijewski, MA, Janjetovic, Z, Li, W, Chen, J, Kusniatsova, EI, Semak, I, Postlethwaite, A, Miller, DD, Zjawiony, JK, Tuckey, RC. Novel vitamin D photoproducts and their precursors in the skin. Dermatoendocrinol, 5 (1), 7-19, 2013.
  19. Wei, W, Jiao, Y, Postlethwaite, A, Stuart, JM, Wang, Y, Sun, D, Gu, W. Dual-specificity phosphatases 2: surprising positive effect at the molecular level and a potential biomarker of diseases. Genes Immun, 14 (1), 1-6, 2013.
  20. Slominski, AT, Kim, TK, Shehabi, HZ, Semak, I, Tang, EK, Nguyen, MN, Benson, HA, Korik, E, Janjetovic, Z, Chen, J, Yates, CR, Postlethwaite, A, Li, W, Tuckey, RC. In vivo evidence for a novel pathway of vitamin D₃ metabolism initiated by P450scc and modified by CYP27B1. FASEB J, 26 (9), 3901-15, 2012.
  21. Brown, M, Postlethwaite, AE, Myers, LK, Hasty, KA. Supernatants from culture of type I collagen-stimulated PBMC from patients with cutaneous systemic sclerosis versus localized scleroderma demonstrate suppression of MMP-1 by fibroblasts. Clin Rheumatol, 31 (6), 973-81, 2012.
  22. Wang, J, Slominski, A, Tuckey, RC, Janjetovic, Z, Kulkarni, A, Chen, J, Postlethwaite, AE, Miller, D, Li, W. 20-hydroxyvitamin D₃ inhibits proliferation of cancer cells with high efficacy while being non-toxic. Anticancer Res, 32 (3), 739-46, 2012.
  23. Cao Y1, Jiao Y, Wang L, Huang Y, Postlethwaite A, Stuart J, Kang A, Williams RW, Gu W. Anakinra as an interleukin 1 receptor antagonist, complicated genetics and molecular impacts--from the point of view of mouse genomics. Int Immunopharmacol, 1 (May 13), 28-36, 2012.
  24. Pattanaik, D, Brown, M, Postlethwaite, AE. Vascular involvement in systemic sclerosis (scleroderma). J Inflamm Res, 4, 105-25, 2011.
  25. Wong WK, Boscardin WJ, Postlethwaite AE, Furst DE. Handling missing data issues in clinical trials for rheumatic diseases.. Contemp Clin Trials, 32 (1), 1-9, 2011.
  26. Slominski, AT, Li, W, Bhattacharya, SK, Smith, RA, Johnson, PL, Chen, J, Nelson, KE, Tuckey, RC, Miller, D, Jiao, Y, Gu, W, Postlethwaite, AE. Vitamin D Analogs 17,20S(OH)(2)pD and 17,20R(OH)(2)pD Are Noncalcemic and Exhibit Antifibrotic Activity. J Invest Dermatol, 2011.
  27. Nashid, M, Khanna, PP, Furst, DE, Clements, PJ, Maranian, P, Seibold, J, Postlethwaite, AE, Louie, JS, Mayes, MD, Agrawal, H, Khanna, D, ,. Gender and ethnicity differences in patients with diffuse systemic sclerosis--analysis from three large randomized clinical trials. Rheumatology (Oxford), 2010.
  28. Atamas, SP, Luzina, IG, Ingels, J, Choi, J, Wong, WK, Furst, DE, Clements, PJ, , , Postlethwaite, AE. Stimulation with type I collagen induces changes in gene expression in peripheral blood mononuclear cells from patients with diffuse cutaneous systemic sclerosis (scleroderma). Clin Exp Immunol, 161 (3), 426-35, 2010.
  29. Pattanaik, D, Postlethwaite, AE. A role for lysophosphatidic acid and sphingosine 1-phosphate in the pathogenesis of systemic sclerosis. Discov Med, 10 (51), 161-7, 2010.
  30. Postlethwaite, AE, Harris, LJ, Raza, SH, Kodura, S, Akhigbe, T. Pharmacotherapy of systemic sclerosis. Expert Opin Pharmacother, 11 (5), 789-806, 2010.
  31. Watsky MA1, Weber KT, Sun Y, Postlethwaite A. New insights into the mechanism of fibroblast to myofibroblast transformation and associated pathologies. Int Rev Cell Mol BIol, 282 (June), 165-92, 2010.
  32. Yin Z1, Carbone LD, Gotoh M, Postlethwaite A, Bolen AL, Tigyi GJ, Murakami-Murofushi K, Watsky MA. Lysophosphatidic acid-activated Cl- current activity in human systemic sclerosis skin fibroblasts. Rheumatology (Oxford), 12 (Dedc 49), 2290-7, 2010.
  33. Kaldas, M, Khanna, PP, Furst, DE, Clements, PJ, Kee Wong, W, Seibold, JR, Postlethwaite, AE, Khanna, D, ,. Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis--assessment of individual body sites in two large randomized controlled trials. Rheumatology (Oxford), 48 (9), 1143-6, 2009.
  34. Amjadi, S, Maranian, P, Furst, DE, Clements, PJ, Wong, WK, Postlethwaite, AE, Khanna, PP, Khanna, D, ,. Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials. Arthritis Rheum, 60 (8), 2490-8, 2009.
  35. Tokumura A, Carbone LD, Yoshioka Y, Morishige J, Kikuchi M, Postlethwaite A, Watsky MA. Elevated serum levels of arachidonoyl-lysophosphatidic acid and sphingosine 1-phosphate in systemic sclerosis. Int J Med Sci, 6 (Jun 4), 168-76, 2009.
  36. Chiang, TM, Postlethwaite, AE. Alteration in protein kinase B (AKT) activity in platelets from patients with systemic sclerosis. Thromb Res, 2008.
  37. Khanna, D, Clements, PJ, Postlethwaite, AE, Furst, DE. Does Incorporation of Aids and Devices Make a Difference in the Score of the Health Assessment Questionnaire-Disability Index? Analysis from a Scleroderma Clinical Trial. J Rheumatol, 35 (3), 466-468, 2008.
  38. Postlethwaite AE, Wong WK, Clements P, Chatterjee S, Fessler B, Kang AH, Korn J, Mayes M, Merkel PA, Molitor JA, Moreland L, Rothfield N, Simms RW, Smith EA, Spiera R, Steen V, Warrington K, White B, Wigley F, Furst DE. A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum, 58 (Jun 6), 1810-22, 2008.
  39. Xiong Q, Jiao Y, Hasty KA, Stuart JM, Postlethwaite A, Kang AH, Gu W. Genetic and molecular basis of quantitative trait loci of arthritis in rat: genes and polymorphisms. J Immunol, 181 (Jul 2), 859-64, 2008.
  40. Postlethwaite, AE, Chiang, TM. Platelet contributions to the pathogenesis of systemic sclerosis. Curr Opin Rheumatol, 19 (6), 574-9, 2007.
  41. Khanna, D, Furst, DE, Wong, WK, Tsevat, J, Clements, PJ, Park, GS, Postlethwaite, AE, Ahmed, M, Ginsburg, S, Hays, RD, ,. Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis. Qual Life Res, 16 (6), 1083-92, 2007.
  42. Chiang, TM, Postlethwaite, AE. A cell model system to study regulation of phosphotidylinositol 3-kinase and protein kinase B activity by cytokines/growth factors produced by type I collagen stimulated immune cells from patients with systemic sclerosis. Biochim Biophys Acta, 1770 (8), 1181-6, 2007.
  43. Kanangat S1, Postlethwaite A, Cholera S, Williams L, Schaberg D. Modulation of virulence gene expression in Staphylococcus aureus by interleukin-1beta: novel implications in bacterial pathogenesis. Microbes Infect, 9 (Mar 3), 408-15, 2007.
  44. Carbone, LD, Warrington, KJ, Barrow, KD, Pugazhenthi, M, Watsky, MA, Somes, G, Ingels, J, Postlethwaite, AE. Pamidronate infusion in patients with systemic sclerosis results in changes in blood mononuclear cell cytokine profiles. Clin Exp Immunol, 146 (3), 371-80, 2006.
  45. Kanangat, S, Postlethwaite, AE, Higgins, GC, Hasty, KA. Novel functions of intracellular IL-1ra in human dermal fibroblasts: implications in the pathogenesis of fibrosis. J Invest Dermatol, 126 (4), 756-65, 2006.
  46. Warrington, KJ, Nair, U, Carbone, LD, Kang, AH, Postlethwaite, AE. Characterisation of the immune response to type I collagen in scleroderma. Arthritis Res Ther, 8 (4), R136, 2006.
  47. Chiang, TM, Postlethwaite, AE. Increase in phosphotidylinositide-3 kinase activity by nitrotyrosylation of lysates of platelets from patients with systemic sclerosis. Biochim Biophys Acta, 1760 (1), 32-7, 2006.
  48. Kanangat S1, Postlethwaite A, Hasty K, Kang A, Smeltzer M, Appling W, Schaberg D. Induction of multiple matrix metalloproteinases in human dermal and synovial fibroblasts by Staphylococcus aureus: implications in the pathogenesis of septic arthritis and other soft tissue infections. Arthritis Res Ther, 8 (6), R176, 2006.
  49. Takagi, K, Takagi, M, Kanangat, S, Warrington, KJ, Shigemitsu, H, Postlethwaite, AE. Modulation of TNF-alpha gene expression by IFN-gamma and pamidronate in murine macrophages: regulation by STAT1-dependent pathways. J Immunol, 174 (4), 1801-10, 2005.
  50. Wang B, Ansari R, Sun Y, Postlethwaite AE, Weber KT, Kiani MF. The scar neovasculature after myocardial infarction in rats. Am J Physiol Heart Circ Physiol, 289 (Jul 1), H108-13, 2005.
  51. Chiang, TM, Takayama, H, Postlethwaite, AE. Increase in platelet non-integrin type I collagen receptor in patients with systemic sclerosis. Thromb Res, 117 (3), 299-306, 2005.
  52. Postlethwaite, AE, Shigemitsu, H, Kanangat, S. Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis. Curr Opin Rheumatol, 16 (6), 733-8, 2004.
  53. Carbone LD, McKown K, Pugazhenthi M, Barrow KD, Warrington K, Somes G, Postlethwaite AE. Dosage effects of orally administered bovine type I collagen on immune function in patients with systemic sclerosis. Arthritis Rheum, 50 (Aug 8), 2713-5, 2004.
  54. Ahokas, RA, Warrington, KJ, Gerling, IC, Sun, Y, Wodi, LA, Herring, PA, Lu, L, Bhattacharya, SK, Postlethwaite, AE, Weber, KT. Aldosteronism and peripheral blood mononuclear cell activation: a neuroendocrine-immune interface. Circ Res, 93 (10), e124-35, 2003.
  55. Weber, KT, Sun, Y, Wodi, LA, Munir, A, Jahangir, E, Ahokas, RA, Gerling, IC, Postlethwaite, AE, Warrington, KJ. Toward a broader understanding of aldosterone in congestive heart failure. J Renin Angiotensin Aldosterone Syst, 4 (3), 155-63, 2003.
  56. Weber, KT, Gerling, IC, Kiani, MF, Guntaka, RV, Sun, Y, Ahokas, RA, Postlethwaite, AE, Warrington, KJ. Aldosteronism in heart failure: a proinflammatory/fibrogenic cardiac phenotype. Search for biomarkers and potential drug targets. Curr Drug Targets, 4 (6), 505-16, 2003.
  57. Gerling, IC, Sun, Y, Ahokas, RA, Wodi, LA, Bhattacharya, SK, Warrington, KJ, Postlethwaite, AE, Weber, KT. Aldosteronism: an immunostimulatory state precedes proinflammatory/fibrogenic cardiac phenotype. Am J Physiol Heart Circ Physiol, 285 (2), H813-21, 2003.
  58. Pugazhenthi M1, Cooper D, Ratnakant BS, Postlethwaite A, Carbone L. Hypercapnic respiratory failure in systemic sclerosis. J Clin Rheumatol, 9 (Feb 1), 43-6, 2003.
  59. Sun, Y, Kiani, MF, Postlethwaite, AE, Weber, KT. Infarct scar as living tissue. Basic Res Cardiol, 97 (5), 343-7, 2002.
  60. Myers, LK, Higgins, GC, Finkel, TH, Reed, AM, Thompson, JW, Walton, RC, Hendrickson, J, Kerr, NC, Pandya-Lipman, RK, Shlopov, BV, Stastny, P, Postlethwaite, AE, Kang, AH. Juvenile arthritis and autoimmunity to type II collagen. Arthritis Rheum, 44 (8), 1775-81, 2001.
  61. Postlethwaite, AE. Can we induce tolerance in rheumatoid arthritis. Curr Rheumatol Rep, 3 (1), 64-9, 2001.
  62. Kanangat S1, Bronze MS, Meduri GU, Postlethwaite A, Stentz F, Tolley E, Schaberg D. Enhanced extracellular growth of Staphylococcus aureus in the presence of selected linear peptide fragments of human interleukin (IL)-1beta and IL-1 receptor antagonist. J Infect Dis, 183 (Jan 1), 65-9, 2001.
  63. Myers, LK, Kang, AH, Postlethwaite, AE, Rosloniec, EF, Morham, SG, Shlopov, BV, Goorha, S, Ballou, LR. The genetic ablation of cyclooxygenase 2 prevents the development of autoimmune arthritis. Arthritis Rheum, 43 (12), 2687-93, 2000.
  64. McKown, KM, Carbone, LD, Bustillo, J, Seyer, JM, Kang, AH, Postlethwaite, AE. Induction of immune tolerance to human type I collagen in patients with systemic sclerosis by oral administration of bovine type I collagen. Arthritis Rheum, 43 (5), 1054-61, 2000.
  65. Higgins, GC, Wu, Y, Postlethwaite, AE. Intracellular IL-1 receptor antagonist is elevated in human dermal fibroblasts that overexpress intracellular precursor IL-1 alpha. J Immunol, 163 (7), 3969-75, 1999.
  66. McKown, KM, Carbone, LD, Kaplan, SB, Aelion, JA, Lohr, KM, Cremer, MA, Bustillo, J, Gonzalez, M, Kaeley, G, Steere, EL, Somes, GW, Myers, LK, Seyer, JM, Kang, AH, Postlethwaite, AE. Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis. Arthritis Rheum, 42 (6), 1204-8, 1999.
  67. Tan FK1, Arnett FC, Antohi S, Saito S, Mirarchi A, Spiera H, Sasaki T, Shoichi O, Takeuchi K, Pandey JP, Silver RM, LeRoy C, Postlethwaite AE, Bona CA. Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with scleroderma and other connective tissue diseases. J Immunol, 163 (Jul 2), 1066-72, 1999.
  68. Meduri GU1, Tolley EA, Chinn A, Stentz F, Postlethwaite A. Procollagen types I and III aminoterminal propeptide levels during acute respiratory distress syndrome and in response to methylprednisolone treatment. Am J Respir Crit Care Med, 158 (Nov 5 Pt 1), 1432-41, 1998.
  69. Postlethwaite, AE. Bidirectional interactions between T cells and the extracellular matrix. Transpl Immunol, 5 (4), 289-91, 1997.
  70. Solomon, SS, Mishra, SK, Palazzolo, MR, Postlethwaite, AE, Seyer, JM. Identification of specific sites in the TNF-alpha molecule promoting insulin resistance in H-411E cells. J Lab Clin Med, 130 (2), 139-46, 1997.
  71. Solomon, SS, Mishra, SK, Cwik, C, Rajanna, B, Postlethwaite, AE. Pioglitazone and metformin reverse insulin resistance induced by tumor necrosis factor-alpha in liver cells. Horm Metab Res, 29 (8), 379-82, 1997.
  72. Higgins, GC, Postlethwaite, AE. Synovial fluid from patients with rheumatoid arthritis contains a unique inhibitor of interleukin 1 alpha. J Rheumatol, 23 (6), 965-73, 1996.
  73. Armendariz-Borunda J1, Endres RO, Ballou LR, Postlethwaite AE. Transforming growth factor-beta inhibits interferon-gamma-induced HLA-DR expression by cultured human fibroblasts. Int J Biochem Cell BIol, 28 (Oct 10), 1107-16, 1996.
  74. Postlethwaite, AE. Connective tissue metabolism including cytokines in scleroderma. Curr Opin Rheumatol, 7 (6), 535-40, 1995.
  75. Postlethwaite, AE, Seyer, JM. Identification of a chemotactic epitope in human transforming growth factor-beta 1 spanning amino acid residues 368-374. J Cell Physiol, 164 (3), 587-92, 1995.
  76. Ballou, LR, Postlethwaite, AE, Kang, AH. The Effect of Misoprostol on Arachidonic Acid Mobilization, Prostaglandin E(2), Production, and IL-1beta Signaling. Am J Ther, 2 (9), 630-636, 1995.
  77. White, B, Bauer, EA, Goldsmith, LA, Hochberg, MC, Katz, LM, Korn, JH, Lachenbruch, PA, LeRoy, EC, Mitrane, MP, Paulus, HE. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis. Arthritis Rheum, 38 (3), 351-60, 1995.
  78. Meduri GU1, Headley S, Tolley E, Shelby M, Stentz F, Postlethwaite A. Plasma and BAL cytokine response to corticosteroid rescue treatment in late ARDS. Chest, 108 (Nov 5), 1315-25, 1995.
  79. Meduri GU1, Kohler G, Headley S, Tolley E, Stentz F, Postlethwaite A. Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome. Chest, 108 (Nov 5), 1303-14, 1995.
  80. Moreland LW, Pratt PW, Mayes MD, Postlethwaite A, Weisman MH, Schnitzer T, Lightfoot R, Calabrese L, Zelinger DJ, Woody JN, Koopman WJ. Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum, 38 (Nov 11), 1581-8, 1995.
  81. Postlethwaite, AE. Role of T cells and cytokines in effecting fibrosis. Int Rev Immunol, 12 (2-4), 247-58, 1995.
  82. Postlethwaite, AE, Raghow, R, Stricklin, G, Ballou, L, Sampath, TK. Osteogenic protein-1, a bone morphogenic protein member of the TGF-beta superfamily, shares chemotactic but not fibrogenic properties with TGF-beta. J Cell Physiol, 161 (3), 562-70, 1994.
  83. Postlethwaite, AE. Connective tissue metabolism including cytokines in scleroderma. Curr Opin Rheumatol, 6 (6), 616-20, 1994.
  84. Higgins, GC, Foster, JL, Postlethwaite, AE. Interleukin 1 beta propeptide is detected intracellularly and extracellularly when human monocytes are stimulated with LPS in vitro. J Exp Med, 180 (2), 607-14, 1994.
  85. Postlethwaite, AE. Connective tissue metabolism including cytokines in scleroderma. Curr Opin Rheumatol, 5 (6), 766-72, 1993.
  86. Hong L1, Imeri L, Opp MR, Postlethwaite AE, Seyer JM, Krueger JM. Intercellular adhesion molecule-1 expression induced by interleukin (IL)-1 beta or an IL-1 beta fragment is blocked by an IL-1 receptor antagonist and a soluble IL-1 receptor. J Neuroimmunol, 44 (May 2), 163-70, 1993.
  87. Postlethwaite, AE, Holness, MA, Katai, H, Raghow, R. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest, 90 (4), 1479-85, 1992.
  88. Kapás, L, Hong, L, Cady, AB, Opp, MR, Postlethwaite, AE, Seyer, JM, Krueger, JM. Somnogenic, pyrogenic, and anorectic activities of tumor necrosis factor-alpha and TNF-alpha fragments. Am J Physiol, 263 (3 Pt 2), R708-15, 1992.
  89. Opp, MR, Postlethwaite, AE, Seyer, JM, Krueger, JM. Interleukin 1 receptor antagonist blocks somnogenic and pyrogenic responses to an interleukin 1 fragment. Proc Natl Acad Sci U S A, 89 (9), 3726-30, 1992.
  90. Armendariz-Borunda, J, Seyer, JM, Postlethwaite, AE, Kang, AH. Kupffer cells from carbon tetrachloride-injured rat livers produce chemotactic factors for fibroblasts and monocytes: the role of tumor necrosis factor-alpha. Hepatology, 14 (5), 895-900, 1991.
  91. Postlethwaite, AE, Seyer, JM. Fibroblast chemotaxis induction by human recombinant interleukin-4. Identification by synthetic peptide analysis of two chemotactic domains residing in amino acid sequences 70-88 and 89-122. J Clin Invest, 87 (6), 2147-52, 1991.
  92. Prakash S1, Postlethwaite AE, Wyler DJ. Alterations in influence of granuloma-derived cytokines on fibrogenesis in the course of murine Schistosoma mansoni infection. Hepatology, 13 (May 5), 970-6, 1991.
  93. Pisetsky DS1, Haynes BF, Lipsky PE, Kang AH, Postlethwaite AE. The specialized centers of research in rheumatoid arthritis. Recent progress and prospects for future advances. Hum Immunol, 87 (Jun 6), 2147-52, 1991.
  94. Ballou, LR, Barker, SC, Postlethwaite, AE, Kang, AH. Interleukin 1 stimulates phosphatidylinositol kinase activity in human fibroblasts. J Clin Invest, 87 (1), 299-304, 1991.
  95. Fava RA1, Olsen NJ, Postlethwaite AE, Broadley KN, Davidson JM, Nanney LB, Lucas C, Townes AS. Transforming growth factor beta 1 (TGF-beta 1) induced neutrophil recruitment to synovial tissues: implications for TGF-beta-driven synovial inflammation and hyperplasia. J Exp Med, 173 (May 5), 1121-32, 1991.
  96. Ballou, LR, Barker, SC, Postlethwaite, AE, Kang, AH. Sphingosine potentiates IL-1-mediated prostaglandin E2 production in human fibroblasts. J Immunol, 145 (12), 4245-51, 1990.
  97. Postlethwaite, AE, Seyer, JM. Stimulation of fibroblast chemotaxis by human recombinant tumor necrosis factor alpha (TNF-alpha) and a synthetic TNF-alpha 31-68 peptide. J Exp Med, 172 (6), 1749-56, 1990.
  98. Obal, F, Opp, M, Cady, AB, Johannsen, L, Postlethwaite, AE, Poppleton, HM, Seyer, JM, Krueger, JM. Interleukin 1 alpha and an interleukin 1 beta fragment are somnogenic. Am J Physiol, 259 (3 Pt 2), R439-46, 1990.
  99. Postlethwaite, AE. Early immune events in scleroderma. Rheum Dis Clin North Am, 16 (1), 125-39, 1990.
  100. Prakash S1, Postlethwaite AE, Stricklin GP, Wyler DJ. Fibroblast stimulation in schistosomiasis. IX. Schistosomal egg granulomas from congenitally athymic mice are deficient in production of fibrogenic factors. J Immunol, 144 (Jan 1), 317-22, 1990.
  101. Cush JJ1, Lipsky PE, Postlethwaite AE, Schrohenloher RE, Saway A, Koopman WJ. Correlation of serologic indicators of inflammation with effectiveness of nonsteroidal antiinflammatory drug therapy in rheumatoid arthritis. Arthritis Rheum, 33 (Jan 1), 19-28, 1990.
  102. Drake, S, Massie, JD, Postlethwaite, AE, Palmieri, GM. Pamidronate sodium and calcitonin-resistant Paget's disease. Immediate response in a patient. Arch Intern Med, 149 (2), 401-3, 1989.
  103. Postlethwaite, AE, Smith, GN, Lachman, LB, Endres, RO, Poppleton, HM, Hasty, KA, Seyer, JM, Kang, AH. Stimulation of glycosaminoglycan synthesis in cultured human dermal fibroblasts by interleukin 1. Induction of hyaluronic acid synthesis by natural and recombinant interleukin 1s and synthetic interleukin 1 beta peptide 163-171. J Clin Invest, 83 (2), 629-36, 1989.
  104. Bever CT Jr1, Snyder DS, Endres RO, Morgan KD, Postlethwaite A, Whitaker JN. Activation of astrocytic lysosomal proteinases by factors released by mononuclear leukocytes. Neurochem Res, 14 (Jan 1), 37-41, 1989.
  105. Postlethwaite, AE, Raghow, R, Stricklin, GP, Poppleton, H, Seyer, JM, Kang, AH. Modulation of fibroblast functions by interleukin 1: increased steady-state accumulation of type I procollagen messenger RNAs and stimulation of other functions but not chemotaxis by human recombinant interleukin 1 alpha and beta. J Cell Biol, 106 (2), 311-8, 1988.
  106. Keski-Oja J1, Raghow R, Sawdey M, Loskutoff DJ, Postlethwaite AE, Kang AH, Moses HL. Regulation of mRNAs for type-1 plasminogen activator inhibitor, fibronectin, and type I procollagen by transforming growth factor-beta. Divergent responses in lung fibroblasts and carcinoma cells. J Biol Chem, 263 (Mar 7), 3111-5, 1988.
  107. Keski-Oja J1, Postlethwaite AE, Moses HL. Transforming growth factors in the regulation of malignant cell growth and invasion. Cancer Invest, 6 (6), 705-24, 1988.
  108. Postlethwaite, AE, Kang, AH. Advantages and limitations of in vitro models of wound healing and tissue repair. Prog Clin Biol Res, 266, 237-42, 1988.
  109. Postlethwaite AE, Kang AH. Fibroblast chemoattractants. Methods Enzymol, 163, 694-707, 1988.
  110. Postlethwaite AE, Keski-Oja J, Moses HL, Kang AH. Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor beta. J Exp Med, 165 (Jan 1), 251-6, 1987.
  111. Ochs ME, Postlethwaite AE, Kang AH. Identification of a protein in sera of normal humans that inhibits fibroblast chemotactic and random migration in vitro. J Invest Dermatol, 88 (Feb 2), 183-90, 1987.
  112. Raghow R, Postlethwaite AE, Keski-Oja J, Moses HL, Kang AH. Transforming growth factor-beta increases steady state levels of type I procollagen and fibronectin messenger RNAs posttranscriptionally in cultured human dermal fibroblasts. J Clin Invest, 79 (Apr 4), 1285-8, 1987.
  113. Wyler DJ, Ehrlich HP, Postlethwaite AE, Raghow R, Murphy MM. Fibroblast stimulation in schistosomiasis. VII. Egg granulomas secrete factors that stimulate collagen and fibronectin synthesis. J Immunol, 83 (Feb 2), 629-36, 1987.
  114. Hernandez AD, Hibbs MS, Postlethwaite AE. Establishment of basal cell carcinoma in culture: evidence for a basal cell carcinoma-derived factor(s) which stimulates fibroblasts to proliferate and release collagenase.. J Invest Dermatol, 85 (Nov 5), 470-5, 1985.
  115. Postlethwaite, AE, Kang, AH. Pathogenesis of progressive systemic sclerosis. J Lab Clin Med, 103 (4), 506-10, 1984.
  116. Floyd, RA, Kuo, CY, Yoo, TJ, Song, A, Postlethwaite, AE, Mainardi, C. Protease inhibition of natural killer (NK) and antibody-dependent cell-mediated cytoxicity (ADCC) activities. J Lab Clin Med, 103 (2), 215-22, 1984.
  117. Kang ES, Postlethwaite A, Schaeffer S, Sawhney B. Endogenous surface phosphorylation reactions and ectokinase activity in the guinea pig T lymphocyte.. Cell Immunol, 87 (Sep 2), 319-26, 1984.
  118. Postlethwaite AE, Lachman LB, Kang AH. Induction of fibroblast proliferation by interleukin-1 derived from human monocytic leukemia cells. Arthritis Rheum, Sep 9, 995-1001, 1984.
  119. Postlethwaite AE, Smith GN, Mainardi CL, Seyer JM, Kang AH. Lymphocyte modulation of fibroblast function in vitro: stimulation and inhibition of collagen production by different effector molecules. J Immunol, 132 (May 5), 2470-7, 1984.
  120. Wyler, DJ, Postlethwaite, AE. Fibroblast stimulation in schistosomiasis. IV. Isolated egg granulomas elaborate a fibroblast chemoattractant in vitro. J Immunol, 130 (3), 1371-5, 1983.
  121. Postlethwaite, AE, Lachman, LB, Mainardi, CL, Kang, AH. Interleukin 1 stimulation of collagenase production by cultured fibroblasts. J Exp Med, 157 (2), 801-6, 1983.
  122. Hibbs, MS, Postlethwaite, AE, Mainardi, CL, Seyer, JM, Kang, AH. Alterations in collagen production in mixed mononuclear leukocyte-fibroblast cultures. J Exp Med, 157 (1), 47-59, 1983.
  123. Postlethwaite, AE, Kang, AH. Induction of fibroblast proliferation by human mononuclear leukocyte-derived proteins. Arthritis Rheum, 26 (1), 22-7, 1983.
  124. Postlethwaite, AE, Kang, AH. Characterization of fibroblast proliferation factors elaborated by antigen- and mitogen-stimulated guinea pig lymph node cells: differentiation from lymphocyte-derived chemotactic factor for fibroblasts, lymphocyte mitogenic factor, and interleukin 1. Cell Immunol, 73 (1), 169-78, 1982.
  125. Postlethwaite, AE, Jackson, BK, Beachey, EH, Kang, AH. Formation of multinucleated giant cells from human monocyte precursors. Mediation by a soluble protein from antigen-and mitogen-stimulated lymphocytes. J Exp Med, 155 (1), 168-78, 1982.
  126. Postlethwaite, AE, Keski-Oja, J, Balian, G, Kang, AH. Induction of fibroblast chemotaxis by fibronectin. Localization of the chemotactic region to a 140,000-molecular weight non-gelatin-binding fragment. J Exp Med, 153 (2), 494-9, 1981.
  127. Postlethwaite, AE. Isolation and characterization of lymphocyte mitogenic factor released in vivo during a cell-mediated immune reaction in the guinea pig. J Immunol, 125 (5), 1955-8, 1980.
  128. Stuart, JM, Postlethwaite, AE, Townes, AS, Kang, AH. Cell-mediated immunity to collagen and collagen alpha chains in rheumatoid arthritis and other rheumatic diseases. Am J Med, 69 (1), 13-8, 1980.
  129. Postlethwaite, AE, Kang, AH. Characterization of guinea pig lymphocyte-derived chemotactic factor for fibroblasts. J Immunol, 124 (3), 1462-6, 1980.
  130. Postlethwaite, AE, Snyderman, R, Kang, AH. Generation of a fibroblast chemotactic factor in serum by activation of complement. J Clin Invest, 64 (5), 1379-85, 1979.
  131. Postlethwaite, AE, Kang, AH. Latent lymphokines: isolation of guinea pig latent lymphocyte-derived chemotactic factor for monocytes. Its activation by trypsin and a soluble factor from macrophages. J Immunol, 123 (2), 561-7, 1979.
  132. Chiang, TM, Postlethwaite, AE, Beachey, EH, Seyer, JM, Kang, AH. Binding of chemotactic collagen-derived peptides to fibroblasts. The relationship to fibroblast chemotaxis. J Clin Invest, 62 (5), 916-22, 1978.
  133. Postlethwaite, AE, Seyer, JM, Kang, AH. Chemotactic attraction of human fibroblasts to type I, II, and III collagens and collagen-derived peptides. Proc Natl Acad Sci U S A, 75 (2), 871-5, 1978.
  134. Townes, AS, Postlethwaite, AE. Lymphocyte surface markers in human disease. Adv Intern Med, 22, 97-119, 1977.
  135. Postlethwaite, AE, Snyderman, R, Kang, AH. The chemotactic attraction of human fibroblasts to a lymphocyte-derived factor. J Exp Med, 144 (5), 1188-203, 1976.
  136. Postlethwaite, AE, Kang, AH. Guinea pig lymphocyte-derived macrophage aggregation factor: its separation from macrophage migration inhibitory factor. J Immunol, 117 (5 Pt 1), 1651-5, 1976.
  137. Postlethywaite, AE, Townes, AS, Kang, AH. Characterization of macrophage migration inhibitory factor activity produced in vivo by a cell-mediated immune reaction in the guinea pig. J Immunol, 117 (5 Pt 1), 1716-20, 1976.
  138. Stuart, JM, Postlethwaite, AE, Kang, AH. Evidence for cell-mediated immunity to collagen in progressive systemic sclerosis. J Lab Clin Med, 88 (4), 601-7, 1976.
  139. Postlethwaite, AE, Kang, AH. Collagen-and collagen peptide-induced chemotaxis of human blood monocytes. J Exp Med, 143 (6), 1299-307, 1976.
  140. Stuart, JM, Postlethwaite, AE, Kang, AH. Proceedings: Evidence of cell-mediated immunity to collagen in patients with progressive systemic sclerosis. Arthritis Rheum, 18 (5), 525-6, 1975.
  141. POSTLETHWAITE, AE, Snyderman, R. Characterization of chemotactic activity produced in vivo by a cell-mediated immune reaction in the guinea pig. J Immunol, 114 (1 Pt 2), 274-8, 1975.
  142. Postlethwaite, AE, Gutman, RA, Kelley, WN. Salicylate-mediated increase in urate removal during hemodialysis: evidence for urate binding to protein in vivo. Metabolism, 23 (8), 771-7, 1974.
  143. Postlethwaite, AE, Ramsdell, CM, Kelley, WN. Uricosuric effect of anticholinergic agent in hyperuricemic subjects. Arch Intern Med, 134 (2), 270-5, 1974.
  144. Ramsdell, CM, Postlethwaite, AE, Kelley, WN. Uricosuric effect of glyceryl guaiacolate. J Rheumatol, 1 (1), 114-6, 1974.
  145. Postlethwaite, AE, Ramsdell, CM, Kelley, WN. Uricosuric effect of an anticholinergic agent in hyperuricemic subjects. Adv Exp Med Biol, 41, 769-76, 1974.
  146. Postlethwaite, AE, Bartel, AG, Kelley, WN. Hyperuricemia induced by ethambutol. Adv Exp Med Biol, 41, 763-7, 1974.
  147. Postlethwaite, AE, Kelley, WN. Studies on the mechanism of ethambutol-induced hyperuricemia. Arthritis Rheum, 15 (4), 403-9, 1972.
  148. Postlethwaite, AE, Bartel, AG, Kelley, WN. Hyperuricemia due to ethambutol. N Engl J Med, 286 (14), 761-2, 1972.
  149. Postlethwaite, AE, Kelley, WN. Radiocontrast agents and aspirin. JAMA, 219 (11), 1479, 1972.
  150. Postlethwaite, AE, Kelley, WN. Uricosuric effect of radiocontrast agents. A study in man of four commonly used preparations. Ann Intern Med, 74 (6), 845-52, 1971.